Get all premium features to the best stock analysis tool

Oxford BioMedica PLC (LSE:OXB) received a reaffirmed 'outperform' rating from RBC Capital Markets on Friday, as the broker shrugged off clinical trial halts at two heavyweight pharmaceutical partners. The shares inched up 1% to 430p in morning trade, with RBC holding its 900p target price and branding the clinical disruption as of limited direct financial relevance.

Deutsche Bank downgraded Oxford BioMedica PLC (LSE:OXB), the cell and gene therapy specialist, to 'hold' from 'buy' and cut its target price to 595p from 800p after slower revenue conversion and programme delays weakened its outlook. The bank's revised target represents a 20.7% premium to Oxford BioMedica's last closing price of 493p, but Deutsche Bank said the burden of proof had shifted towards execution.

RBC Capital Markets has slashed its price target for Oxford BioMedica PLC (LSE:OXB) to 900p from 1,140p after last week's guidance downgrade, while keeping its outperform rating on the gene therapy manufacturer. Charles Weston has cut revenue forecasts by 17% across each of the next three years and trimmed 5 percentage points from his margin assumptions.

Shares in Oxford BioMedica PLC (LSE:OXB) fell 19% to 479p after the cell and gene therapy manufacturer cut its 2026 guidance, a reaction that reflects the scale of the earnings hit rather than the revenue shortfall alone. Peel Hunt and Stifel, the two brokers to publish on the update, both put the revenue downgrade at about 17% against consensus.

Britain's Oxford Biomedica fell more than 24% on Friday ​after the cell and gene therapy manufacturer ‌cut its 2026 revenue forecast, citing operational delays at a U.S. site and deferred client orders.

Oxford BioMedica PLC (LSE:OXB), the cell and gene therapy manufacturer, has cut its revenue guidance for 2026 after clients deferred orders and a US site took longer than expected to come online. The company now expects full-year revenues of £180 million to £200 million.